HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX <em>ERBB2</em> mRNA score as a prognostic predic...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez-Bayona, Rodrigo, Martínez-Sáez, Olga, Romero-Romero, Denys, Seguí, Elia, Carcelero San Martin, Esther, Tolosa, Pablo, Soberino, Jesús, Alva, Manuel, Pascual, Tomás, Lema, Laura, Garcia-Fructuoso, Isabel, Cobos-Fernandez, Maria Angeles, Rey, Maria, Manso, Luis, Aguirre, Ángela, Madariaga, Ainhoa, Sirenko, Valeria, González-Deza, Cristina, Blasco, Paula, Mayhua, Astrid, Castillo, Oleguer, Galván, Patricia, Sanfeliu Torres, Esther, Villacampa, Guillermo, Buckingham, Wesley, Marín-Aguilera, Mercedes, Paré, Laia, Villagrasa, Patricia, Perou, Charles M., Maues, Julia, Brasó-Maristany, Fara, Ciruelos, Eva, Prat Aparicio, Aleix
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/227133
Acceso en línea:https://hdl.handle.net/2445/227133
Access Level:acceso abierto
Palabra clave:Càncer de mama
Oncologia
Breast cancer
Oncology
Descripción
Sumario:In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX <em>ERBB2</em> mRNA score as a prognostic predictor, aiming to tailor treatment strategies. We retrospectively analyzed 94 patients treated with the THP regimen between 2010 and 2024. The HER2DX <em>ERBB2</em> mRNA score was categorized as low (<em>n</em> = 14), medium (<em>n</em> = 20), or high (<em>n</em> = 60), and its correlation with progression-free survival (PFS) and overall survival (OS) was assessed using Cox regression models. The median follow-up was 31.5 months. Patients with <em>ERBB2</em>-high scores had significantly better median PFS (33.9 vs. 10.6 months, hazard ratio [HR] = 0.40, 95% CI: 0.24–0.69, <em>p</em> < 0.001) and OS (not reached vs. 30.8 months, HR = 0.26, 95% CI: 0.13–0.49, <em>p</em> < 0.001) compared to <em>ERBB2</em>-low patients. Based on these findings, further validation of this biomarker in tumor samples from the CLEOPATRA phase III trial is ongoing, which could help optimize treatment strategies in this population.

Similares en LA Referencia